Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

ConferencepositivelaromestrocelPositive

AI Analysis

Summary

Longeveron announced presentation of clinical data at the 2026 Alzheimer's Association International Conference showing that its stem cell therapy laromestrocel reduced neuroinflammation in patients with mild Alzheimer's disease.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Clinical data showed laromestrocel reduced neuroinflammation in patients with mild Alzheimer's disease

Importance:5/10

Sentiment:

0.60

Alzheimer's Diseasestem cell therapyneuroinflammationclinical dataconference presentation

Related Companies

$LGVN

Read the original article

Published by GlobeNewswire Clinical Studies on July 13, 2026 11:05 AM

Read Original